Seelos Therapeutics has dosed the first subject in an open-label basket study of an investigational therapy, SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion), to treat amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease) patients in Australia.
NEW YORK, Aug. 10, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that, on August 7, 2020, it was notified by the Food and Drug Administration (FDA) that Seelos may proceed with initiating a Phase IIb/III trial studying SLS-005 (trehalose) for the treatment of Amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).
NEW YORK, July 21, 2020 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it has received a positive opinion on European Orphan Drug Designation for SLS-005 in Sanfilippo syndrome from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP).
Bioblast Pharma Announces Sale of its Trehalose Clinical Development Programs to Seelos Therapeutics
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today a definitive agreement with Bioblast Pharma Ltd., (Nasdaq: ORPN), whereby Seelos acquired all development and commercial rights to Bioblast’s proprietary trehalose 90 mg/mL IV (Trehalose) solution as well as the existing inventory of the drug which should be sufficient to fulfill its current research needs. Trehalose, which is currently an investigational molecule, has been studied in prior phase 2 clinical studies in over 70 patients with two rare diseases and demonstrated a favorable safety profile and promising efficacy signal.